Medicine and Dentistry
Patient
100%
Therapeutic Procedure
38%
Neoplasm
34%
Pancreas Cancer
26%
Inpatient
25%
Overall Survival
20%
Immune Checkpoint Inhibitor
12%
Malignant Neoplasm
11%
Breast Cancer
11%
Diagnosis
11%
Diseases
9%
Hepatocellular Carcinoma
9%
Gemcitabine
8%
Cancer
8%
Prognosis
8%
Survival
8%
Chemotherapy
8%
Cancer Therapy
7%
Lymph Node
7%
Age
7%
Tissues
7%
Breast Tumor
7%
Carcinoma
7%
Non Small Cell Lung Cancer
6%
Programmed Death-Ligand 1
6%
Cancer Staging
6%
Clinical Trial
6%
Neuroendocrine Carcinoma
6%
Stereology
6%
Adjuvant Chemotherapy
5%
Immunotherapy
5%
Progression Free Survival
5%
Bevacizumab
5%
Assessment
5%
Histopathology
5%
Clinical Stage
5%
Retrospective Study
5%
Erlotinib
5%
Biological Marker
5%
Upper Gastrointestinal Cancer
5%
Combination Chemotherapy
5%
Prognostic Factor
5%
Measurement
5%
Sorafenib
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
16%
Diseases
7%
Pancreas Cancer
7%
Overall Survival
6%
Neoplasm
6%
Erlotinib
5%